WMIS Supports Experts, Commits to Resolve Beta Amyloid Issues with CMS

Based upon the scientific evidence acquired over the years, WMIS supports the position that Beta Amyloid PET Imaging does change the health outcomes. This position is similar to the testimony of several experts who presented during the MEDCAC meeting.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Washington DC (PRWEB) February 07, 2013

On January 30th, 2013 CMS (Centers for Medicare & Medicaid Services) held the MEDCAC (Medicare Evidence Development & Coverage Advisory Committee) meeting to review the available evidence and hear public testimony on the use of beta amyloid PET imaging for the management of dementia and neurodegenerative disease. At the conclusion of the presentations and discussion, the panel voted ‘low to intermediate’ confidence in evidence supporting the PET imaging of brain beta amyloid to change health outcomes (improved, equivalent or worsened) in patients who display early symptoms or signs of cognitive dysfunction.
Based upon the scientific evidence acquired over the years, WMIS supports the position that PET Imaging does change the health outcomes. This position is similar to the testimony of several experts who presented during the meeting. “We stay firm in our belief that PET imaging can truly help improve health outcomes in patients and we support the testimony of the medical experts. We are committed to work with CMS to resolve any outstanding issues about beta amyloid imaging.” said Kim Pierce, Executive Director of WMIS.

WMIS is the molecular imaging sector’s largest source of information and data on reimbursement since it manages the NOPR. The National Oncologic PET Registry (NOPR) is a collaboration of the American College of Radiology Imaging Network (ACRIN), the American College of Radiology (ACR), and the World Molecular Imaging Society (WMIS), to ensure access to Medicare reimbursement for certain types of positron emission tomography (PET) scans.

The testimony of medical experts clearly demonstrated that significant evidence already exists. “It is important to recognize that the panel is concerned about insufficient evidence and is not questioning the fundamental premise of the diagnostic test. We invite CMS to work with the industry and molecular imaging societies to receive further clarification. We firmly believe that the opinions of the well-recognized experts in the field should be given priority to determine the future of this FDA approved powerful innovation.” Kim Pierce added.

About WMIS
WMIS is an academic and professional society for Molecular Imaging. From leading projects such as PET awareness campaigns and registry management on the clinical side to developing powerful preclinical models and training programs, WMIS is active across the entire spectrum of Molecular Imaging. WMIS is the world's most innovative and leading society in molecular imaging and molecular medicine. With the rise of the molecular imaging industry and the associated research, WMIS is the only organization that is connecting all the dots in the industry and is working to bring all stakeholders together by Smashing the Silos and Leading Innovation Convergence in molecular medicine through imaging; both for practitioners and researchers, who are defining the future of molecular imaging, WMIS enhances the potential and applications of innovation. http://www.wmis.org


Contact

  • Al Naqvi
    PlanClear Co.
    703-421-2229
    Email